Currently, no approved antiviral drugs target dengue virus (DENV) infection, leaving treatment reliant on supportive care. DENV vaccine efficacy varies depending on the vaccine type, the circulating serotype, and vaccine coverage. We investigated defective interfering particles (DIPs) and lipid nanoparticles (LNPs) to deliver DI290, an anti-DENV DI RNA. Both DIPs and DI290-loaded LNPs (LNP-290) effectively suppressed DENV infection in human primary monocyte-derived macrophages (MDMs), THP-1 macrophages, and fibroblasts-natural DENV targets. Inhibiting interferon (IFN) signaling with a Janus kinase 1/2 inhibitor or an IFN-a/ß receptor 1 (IFNAR1)-binding antibody blocked DIP and LNP-290 antiviral activity. LNP-290 demonstrated a greater than log10 inhibition of DENV viral loads in IFNAR-deficient (Ifnar-/- ) and IFN regulatory factor (IRF) 3 and 7 double knockout (Irf3/7-/- ) mice. Pathway analysis of RNA sequencing data from LNP-treated C57BL/6J mice, Ifnar-/- mice, and human MDMs treat...
| Authors | Lin, MH; Maniam, P; Li, D; Tang, B; Bishop, CR; Suhrbier, A; Earl, LW; Tayyar, Y; McMillan, NAJ; Li, L; Harrich, D |
|---|---|
| Journal | Molecular therapy. Nucleic acids |
| Pages | 102424 |
| Volume | 36 |
| Date | 12/01/2024 |
| Grant ID | |
| Funding Body | |
| URL | http://www.ncbi.nlm.nih.gov/pubmed/?term=10.1016/j.omtn.2024.102424 |